FOR US HEALTHCARE PROFESSIONALS ONLY
INVEGA TRINZA® prolactin data
Observed in the double-blind phase
Prolactin elevations1,2*
Potentially prolactin-related adverse reactions1,3†
Observed in the open-label phase*†
Prolactin elevations1,2*
Potentially prolactin-related adverse reactions1,3†
| Most commonly observed potentially prolactin-related adverse reactions (≥3%) | ||
|---|---|---|
| FEMALES | MALES | |
| Amenorrhea | 4.7% (6/127) | Not applicable |
| Galactorrhea | 3.1% (4/127) | 0% (0/379) |
HYPERPROLACTINEMIA: As with other drugs that antagonize dopamine D2 receptors, INVEGA TRINZA® elevates prolactin levels, and the elevation persists during chronic administration. Paliperidone has a prolactin-elevating effect similar to risperidone, which is associated with higher levels of prolactin elevation than other antipsychotic agents.1
References: 1. INVEGA TRINZA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Data on file. Janssen Pharmaceuticals, Inc. 3. Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830-839.